z-logo
Premium
Mitogenic CA2+ entry through ICRAC channels reciprocally regulates the tumor suppressor guanylyl cyclase C (GCC)
Author(s) -
Frick G. S.,
Kazerounian S.,
Shah F. J.,
Madesh M.,
RuizStewart I.,
Schulz S.,
Hajanóczky G.,
Waldman S. A.,
Pitari G. M.
Publication year - 2004
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2003.11.180
Subject(s) - intracellular , extracellular , cell growth , chemistry , soluble guanylyl cyclase , microbiology and biotechnology , forskolin , signal transduction , thapsigargin , cancer research , receptor , biochemistry , biology , guanylate cyclase
Guanylyl cyclase C (GCC) through cyclic GMP (cGMP) inhibits colorectal cancer cell proliferation, serving as a tumor suppressor in intestine. Conversely, Ca 2+ entry through calcium release‐activated calcium (I crac ) channels promotes colorectal cancer growth. The present study explored the functional relationship between mitogenic signaling by Ca 2+ entry through I crac channels and antiproliferative signaling by GCC in T84 human colon carcinoma cells. The E. coli heat‐stable enterotoxin ST, a specific GCC ligand, induced intracellular accumulation of cGMP, Ca 2+ entry through CNG channels and inhibition of human colorectal cancer cell proliferation. In contrast, influx of extracellular Ca 2+ through I crac channels, induced by thapsigargin, UTP or carbachol, inhibited GCC‐dependent cGMP accumulation. Chelating intracellular Ca 2+ , removing extracellular Ca 2+ , or specifically blocking I crac channels with the antagonist 2‐APB reversed this inhibition. Moreover, 2‐APB blocked Ca 2+ ‐dependent cell proliferation and amplified the anti‐proliferative effects of ST. These data suggest that an imbalance of pro‐ and anti‐mitogenic signals mediated by Ca 2+ may contribute to mechanisms underlying colorectal carcinogenesis. In addition, they suggest that the combination of GCC agonists and I crac channel inhibitors represents a novel paradigm for cGMP‐directed therapy for colorectal tumors. Clinical Pharmacology & Therapeutics (2004) 75 , P48–P48; doi: 10.1016/j.clpt.2003.11.180

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom